Markets:

Overview

News

Currencies

International

Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

116.39 +2.36 (+2.07%)

Delayed Quote Updated: 1:21 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks

September 28, 2026

Looking back on branded pharmaceuticals stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Merck (NYSE:MRK) and its peers. L...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Corcept Announces Planned Leadership Transition

September 23, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

Branded Pharmaceuticals Stocks Q2 In Review: Phibro Animal Health (NASDAQ:PAHC) Vs Peers

September 22, 2026

Let’s dig into the relative performance of Phibro Animal Health (NASDAQ:PAHC) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnin...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 of Wall Street’s Favorite Stocks We Keep Off Our Radar

September 22, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Via StockStory

Corcept Therapeutics (NASDAQ:CORT) Combines Strong Growth With a Constructive Technical Setup ↗

September 17, 2026

Via Chartmill

Corcept Therapeutics (NASDAQ:CORT) Surges 21% After Q2 Earnings Beat and Raised Guidance ↗

July 29, 2026

Via Chartmill

Topics Earnings

Corcept Therapeutics Inc (NASDAQ:CORT) Shows Strong Growth Fundamentals and Technical Breakout Setup ↗

July 11, 2026

Via Chartmill

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

September 18, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

2 Healthcare Stocks to Research Further and 1 We Find Risky

September 16, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...

Via StockStory

1 Growth Stock Set to Flourishand 2 We Brush Off

September 01, 2026

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...

Via StockStory

Topics Supply Chain

Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest

August 31, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Q2 Rundown: Pfizer (NYSE:PFE) Vs Other Branded Pharmaceuticals Stocks

August 24, 2026

Let’s dig into the relative performance of Pfizer (NYSE:PFE) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnings season. Lookin...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Mid-Cap Stock for Long-Term Investors and 2 That Underwhelm

August 21, 2026

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...

Via StockStory

Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)

August 19, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Corcept (NASDAQ:CORT) and its...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Surging Stock to Own for Decades and 2 We Brush Off

August 13, 2026

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne...

Via StockStory

3 Cash-Producing Stocks We Steer Clear Of

August 04, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

Corcept Therapeutics Q2 Earnings Call Highlights ↗

July 29, 2026

Corcept Therapeutics (NASDAQ:CORT) reported second-quarter 2026 revenue of $256.1 million, up 32% from the prior-year period, as sales from its Cushing’s syndrome franchise increased and its newly...

Via MarketBeat

Topics Earnings

Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗

July 29, 2026

Via Chartmill

Corcept (NASDAQ:CORT) Reports Bullish Q2 CY2026, Stock Jumps 17.4%

July 29, 2026

Biopharma company Corcept Therapeutics (NASDAQ:CORT) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 31.7% year on year t...

Via StockStory

Topics Artificial Intelligence

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

July 29, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept (CORT) Q2 Earnings: What To Expect

July 27, 2026

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Wednesday after market hours. Here’s what to expect. Corcept mi...

Via StockStory

Topics Artificial Intelligence

Why Corcept (CORT) Stock Is Down Today

July 27, 2026

What Happened? Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 2.9% in the morning session after Wolfe Research downgraded the stock to '...

Via StockStory

Spotting Winners: Corcept (NASDAQ:CORT) And Branded Pharmaceuticals Stocks In Q1

July 26, 2026

Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season. Lo...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

July 22, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know ↗

July 20, 2026

Atabak exercised options and immediately liquidated shares under a pre-established Rule 10b5-1 trading plan adopted in December 2025.

Via The Motley Fool

Topics Regulatory Compliance

A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound ↗

July 20, 2026

This sale was executed under a Rule 10b5-1 trading plan adopted in March, while the stock has gained 25% over the past year.

Via The Motley Fool

Topics Regulatory Compliance

Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook ↗

July 12, 2026

William Guyer's pre-scheduled disposition under a Rule 10b5-1 plan liquidates some direct holdings while retaining 130,000 derivative securities.

Via The Motley Fool

Topics Regulatory Compliance

3 Cash-Heavy Stocks with Questionable Fundamentals

July 07, 2026

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...

Via StockStory

3 High-Flying Stocks We Steer Clear Of

June 30, 2026

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta...

Via StockStory

3 Unpopular Stocks We Steer Clear Of

June 23, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.